Vera Therapeutics Inc. (VERA) Reports Q4 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
March 24, 2022 6:30 AM EDTPhase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 Acquired MAU868, a first-in-class monoclonal antibody to treat BK Virus infections, full results from interim analysis of Phase 2 study of MAU868 in kidney transplant recipients planned for mid-2022Initiation of Phase 3 pivotal clinical trial of atacicept in lupus nephritis planned for 2H-2022 BK Virus and MAU868 key opinion leader webinar to be held Tuesday, March 29, 2022Management to host business update webcast today at 8:00 a.m. ET
BRISBANE, Calif., March 24, 2022 (GLOBE... More
